montelukast

• adverse events incidence

  no effect

  There was no significant difference in the incidence of adverse events between the placebo and montelukast

  PMID:28567533 · one of two readings recorded this

• frequency of wheezing episodes (symptoms treated with beta agonists) over 12 months, pooled mean difference, montelukast versus placebo in preschool children; also unscheduled medical attendances and oral corticosteroid courses

  no effect

  Not recorded as a finding: this platform holds no node for the endpoint

  Trials showed no effects of montelukast in preventing episodes of wheeze.

  PMID:28567533 · one of two readings recorded this

• number of oral corticosteroid courses

  no effect

  It showed no statistically significant difference between montelukast and placebo in reducing the number of OCS (MD = −0.11, 95% CI −0.36 to 0.14)

  PMID:28567533 · one of two readings recorded this

• number of oral corticosteroid courses

  no effect, p = 0.14

  The pooled estimate of the other two studies showed that montelukast did not significantly reduce the number of OCS courses (MD = −0.06, 95% CI −0.15 to 0.02, p = 0.14)

  PMID:28567533 · one of two readings recorded this

• number of oral corticosteroid courses

  no effect, p = 0.25

  This trial reported no significant difference between montelukast and placebo in reducing the number of OCS courses (OR, 0.80; 95% CI, 0.56 to 1.15; mean for montelukast 0.35 vs placebo 0.36 (p = 0.25))

  PMID:28567533 · one of two readings recorded this

• number of unscheduled medical attendances

  no effect

  One study described no statistically significant difference in the number of USMA between montelukast and placebo (MD = −0.04, 95% CI −0.26 to 0.18)

  PMID:28567533 · one of two readings recorded this

• number of wheezing episodes over 12 months (symptoms treated with beta agonists), intermittent montelukast versus placebo in preschool children with recurrent wheeze

  no effect, MD = 0.07, 95% CI −0.14 to 0.29; mean for montelukast 2.68 vs placebo 2.54, p = 0.5

  Not recorded as a finding: this platform holds no node for the endpoint

  The pooled estimate showed no statistically significant difference (MD = 0.07, 95% CI −0.14 to 0.29, mean for montelukast 2.68 vs placebo 2.54 (p = 0.5)).

  PMID:28567533 · one of two readings recorded this

• number of wheezing episodes

  no effect, p = 0.18, n = 1691

  The pooled estimate comparing the number of wheezing episodes was not statistically significant (MD = −0.40, 95% CI −1.00 to 0.19, mean for montelukast 2.05 vs placebo 2.37 (p = 0.18))

  PMID:28567533 · one of two readings recorded this

• number of wheezing episodes

  no effect, p = 0.5

  The pooled estimate showed no statistically significant difference (MD = 0.07, 95% CI −0.14 to 0.29, mean for montelukast 2.68 vs placebo 2.54 (p = 0.5))

  PMID:28567533 · one of two readings recorded this

• patients with at least one unscheduled medical attendance

  no effect

  The other showed no statistical significance in the number of patients presenting with at least one USMA (MD = −0.11, 95% CI −0.36 to 0.14)

  PMID:28567533 · one of two readings recorded this

• percentage of episodes requiring oral corticosteroids

  no effect

  In one trial, only the percentage of episodes that required OCS was presented (21% montelukast vs 24% placebo)

  PMID:28567533 · one of two readings recorded this

• unscheduled medical attendances

  no effect, p = 0.21

  The overall effect was not statistically significant (MD = −0.13, 95% CI −0.33 to 0.07, mean for montelukast 1.62 vs placebo 1.78 (p = 0.21))

  PMID:28567533 · one of two readings recorded this

• adverse events

  no effect

  Two studies reported AEs comparing SFC and MON, both with no significant differences

  PMID:34784306 · one of two readings recorded this

• Childhood Asthma Control Test score

  increases, p = 0.001

  with higher C-ACT score after 4 weeks of treatment (MD: 2.30; 95% CI: 1.39–3.21; I2 = 72%; P < 0.001; Supplementary Appendix 6 Figure 3)

  PMID:34784306 · one of two readings recorded this

• full controlled asthma level

  increases, p = 0.001

  The SFC group showed significantly higher full controlled level (RR: 1.51; 95% CI: 1.24–1.85; I2 = 0; P < 0.001; Supplementary Appendix 6 Figure 1)

  PMID:34784306 · one of two readings recorded this

• PEF%pred after 4 weeks, salmeterol/fluticasone versus montelukast plus fluticasone, in children and adolescents with asthma

  increases, MD 5.45; 95% CI 1.57-9.34, favouring salmeterol/fluticasone over montelukast plus fluticasone, p = 0.006

  Not recorded as a finding: the comparison was against another active treatment

  The SFC group showed a significant improvement of PEF%pred after 4 weeks (MD: 5.45; 95% CI: 1.57–9.34; I2 = 95%; P = 0.006; Figure 3).

  PMID:34784306 · one of two readings recorded this

• PEF%pred

  increases, p = 0.006

  The SFC group showed a significant improvement of PEF%pred after 4 weeks (MD: 5.45; 95% CI: 1.57–9.34; I2 = 95%; P = 0.006; Figure 3)

  PMID:34784306 · one of two readings recorded this

• risk of asthma exacerbation

  no effect, n = 63

  Lenney 2013, UK | 10.39 (6.5–14.67) | Uncontrolled asthma | 63 | SFC vs. MFC | SFC: Inhaled 50 μg/100 μg BID vs. MFC: Oral 5 mg QD/100 μg BID for 48 weeks | 24 weeks and 48 weeks | No significant differences

  PMID:34784306 · one of two readings recorded this

• risk of asthma exacerbation

  decreases, p = 0.001, n = 548

  Maspero 2008, Latin America and Turkey | 9.3 (6–14) | Persistent asthma | 548 | SFC vs. MON | SFC: Inhaled 50 μg/100 μg BID vs. MON: Oral 5 mg QD for 12 weeks | 12 weeks | SFC treatment decreased risk of asthma exacerbation (10.3% vs. 23.2%, P < 0.001)

  PMID:34784306 · one of two readings recorded this

• risk of asthma exacerbation

  no effect, n = 75

  Zhang 2009, China | 8.6 (6–13) | Moderate persistent asthma | 75 | SFC vs. MFC | SFC: Inhaled 50 μg/100 μg BID vs. MFC: Oral 5 mg QD/125 μg BID for 12 weeks | 12 weeks | No significant differences

  PMID:34784306 · one of two readings recorded this

• risk of hospitalization

  no effect, n = 63

  Lenney 2013, UK | 10.39 (6.5–14.67) | Uncontrolled asthma | 63 | SFC vs. MFC | SFC: Inhaled 50 μg/100 μg BID vs. MFC: Oral 5 mg QD/100 μg BID for 48 weeks | 24 weeks and 48 weeks | No significant differences

  PMID:34784306 · one of two readings recorded this

• risk of hospitalization

  no effect, n = 189

  Sorkness 2007, USA | 10 (6–14) | Mild to moderate persistent asthma | 189 | SFC vs. MON | SFC: Inhaled 50 μg/100 μg BID vs. MON: Oral 5 mg QD for 48 weeks | 48 weeks | No significant differences

  PMID:34784306 · one of two readings recorded this

• uncontrolled asthma level

  decreases, p = 0.001

  lower uncontrolled level (RR: 0.35; 95% CI: 0.24–0.52; I2 = 0; P < 0.001; Supplementary Appendix 6 Figure 2)

  PMID:34784306 · one of two readings recorded this

• FEV1/FVC%

  increases, p = 0.01

  three studies, which recorded the FEV1/FVC% index (SMD = 0.76, 95% CI [0.51, 1.01], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• FEV1% (percent predicted)

  increases, p = 0.01

  A noticeable difference in favor of the montelukast adjuvant group (SMD = 0.91, 95% CI [0.40, 1.41], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• FEV1% (percent predicted)

  increases, p = 0.01

  the difference between groups was statistically significant (SMD = 0.65, 95% CI [0.34, 0.97], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• FEV1

  increases, p = 0.01

  the FEV1 was improved by montelukast adjuvant therapy with a statistical difference (SMD = 1.15, 95% CI [0.53, 1.77], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• FEV1

  increases, p = 0.01

  the conclusion that montelukast improved FEV1 remained unchanged (SMD = 0.77, 95% CI [0.59, 0.95], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• incidence of adverse reactions, pooled fixed-effects

  no effect, RR = 1.32, 95% CI [0.89, 1.96], p = 0.17

  Not recorded as a finding: adverse-reaction nodes require reactions attributed to a study product or an oral supplement; this is any adverse event in a drug add-on comparison

  Although a higher incidence of adverse reactions was seen in the montelukast adjuvant group, the meta‐analysis with the fixed‐effects model showed no statistical difference compared to the control group (RR = 1.32, 95% CI [0.89, 1.96], P = 0.17).

  PMID:37218346 · one of two readings recorded this

• incidence of adverse reactions

  no effect, p = 0.17

  no statistical difference compared to the control group (RR = 1.32, 95% CI [0.89, 1.96], P = 0.17)

  PMID:37218346 · one of two readings recorded this

• peak expiratory flow (PEF), pooled SMD

  increases, SMD = 0.64, 95% CI [0.42, 0.86]

  Not recorded as a finding: no outcome node for peak expiratory flow

  The results using the fixed‐effects model demonstrated an obvious difference in favor of the montelukast adjuvant group (SMD = 0.64, 95% CI [0.42, 0.86], P < 0.01).

  PMID:37218346 · one of two readings recorded this

• PEF% (percent predicted)

  increases, p = 0.01

  An obvious difference in favor of the montelukast adjuvant group was demonstrated (SMD = 0.63, 95% CI [0.38, 0.88], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• PEF

  increases, p = 0.01

  demonstrated an obvious difference in favor of the montelukast adjuvant group (SMD = 0.64, 95% CI [0.42, 0.86], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• publication bias for total effective rate (Begg's test)

  no effect, p = 0.079

  The result of Begg's test showed that the total effective rate of this study had no publication bias (P = 0.079)

  PMID:37218346 · one of two readings recorded this

• recurrence rate after 6 months follow-up, pooled RR

  decreases, RR = 0.28, 95% CI [0.15, 0.53]

  Not recorded as a finding: no outcome node for cough variant asthma recurrence rate

  The fixed‐effect model was then conducted and indicated that montelukast adjuvant treatment reduced the recurrence rate (RR = 0.28, 95% CI [0.15, 0.53], P < 0.01).

  PMID:37218346 · one of two readings recorded this

• recurrence rate of cough variant asthma after 6 months follow-up

  decreases, RR = 0.28, 95% CI [0.15, 0.53]

  Not recorded as a finding: no outcome node for asthma or cough recurrence rate

  The fixed‐effect model was then conducted and indicated that montelukast adjuvant treatment reduced the recurrence rate (RR = 0.28, 95% CI [0.15, 0.53], P < 0.01).

  PMID:37218346 · one of two readings recorded this

• recurrence rate

  decreases, p = 0.01

  montelukast adjuvant treatment reduced the recurrence rate (RR = 0.28, 95% CI [0.15, 0.53], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• total effective rate

  increases, p = 0.01

  the total effective rate of montelukast adjuvant treatment was higher than that in the control group (RR = 1.20, 95% CI [1.13, 1.27], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• total effective rate

  increases, p = 0.01

  demonstrated a statistical difference in favor of the montelukast adjuvant group (RR = 1.19, 95% CI [1.09, 1.29], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• total effective rate

  increases, p = 0.01

  the conclusion that montelukast improved the total effective rate remained unchanged (RR = 1.23, 95% CI [1.08, 1.39], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• total effective rate

  increases, p = 0.01

  the total effective rate was higher in the montelukast adjuvant group compared to the control group (RR = 1.17, 95% CI [1.07, 1.28], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• total effective rate

  increases, p = 0.01

  showed that the montelukast adjuvant treatment group had a higher total effective rate (RR = 1.27, 95% CI [1.10, 1.45], P < 0.01)

  PMID:37218346 · one of two readings recorded this

• asthma daytime, night-time and global symptom scores as patient-reported outcome measures, pooled as standardised mean difference across instruments, montelukast versus placebo and versus inhaled corticosteroids in children

  global symptoms SMD 0.90 (95% CI 0.44-1.36) versus placebo; daytime 0.11 (0.05-0.18); night-time 0.15 (0.09-0.21)

  Not recorded as a finding: this platform holds no node for the endpoint

  Pooled estimators of daytime, night-time symptoms and global symptoms scores (and c) showed a statistically significant difference in favour of montelukast: 0.11 (95% CI 0.05–0.18), 0.15 (95% CI 0.09–0.21) and 0.90 (95% CI 0.44–1.36).

  PMID:37852659 · one of two readings recorded this

• asthma symptoms (daytime, night-time, global)

  unclear, p = 0.001

  The subgroup analysis by type of asthma was statistically significant (p<0.001)

  PMID:37852659 · one of two readings recorded this

• daytime asthma symptoms

  decreases

  0.11 (95% CI 0.05–0.18)

  PMID:37852659 · one of two readings recorded this

• daytime asthma symptoms

  increases

  Figure 4a and b shows forest plots of studies comparing patients with asthma treated with ICS versus montelukast in terms of daytime (n=386 intervention, n=376 control) and night-time (n=363 intervention, n=363 control) symptoms, which showed a statistically significant difference in favour of ICS

  PMID:37852659 · one of two readings recorded this

• daytime, night-time and global asthma symptom scores in children, standardised mean difference of change across mixed patient-reported instruments, montelukast versus placebo (HRQoL was pooled only against inhaled corticosteroids)

  global symptom score SMD 0.90 (95% CI 0.44-1.36); daytime 0.11 (0.05-0.18); night-time 0.15 (0.09-0.21)

  Not recorded as a finding: this platform holds no node for the endpoint

  Pooled estimators of daytime, night-time symptoms and global symptoms scores (and c) showed a statistically significant difference in favour of montelukast: 0.11 (95% CI 0.05–0.18), 0.15 (95% CI 0.09–0.21) and 0.90 (95% CI 0.44–1.36).

  PMID:37852659 · one of two readings recorded this

• global asthma symptoms

  decreases

  0.90 (95% CI 0.44–1.36)

  PMID:37852659 · one of two readings recorded this

• global asthma symptoms

  no effect

  When assessing the symptoms globally, there were no differences between montelukast and ICS (−0.04, 95% CI −0.55–0.47)

  PMID:37852659 · one of two readings recorded this

• global health-related quality of life (SMD of change)

  no effect

  which included six studies with a sample size of 656 participants for the intervention group, and 535 for the control group (ICS in monotherapy); the pooled estimator was −0.06 (95% CI −0.14–0.02)

  PMID:37852659 · one of two readings recorded this

• global health-related quality of life (SMD of change)

  no effect

  the HRQoL forest plot of the two studies comparing montelukast with ICS/LABA was in favour of the latter group without statistically significant differences: overall estimator −0.13 (95% CI −0.28–0.02)

  PMID:37852659 · one of two readings recorded this

• global health-related quality of life (SMD of change)

  unclear, p = 0.001

  The subgroup analysis was statistically significant (p<0.001)

  PMID:37852659 · one of two readings recorded this

• mental and physical domains of health-related quality of life

  no effect

  Figure 3c and d shows forest plots of mental and physical domains constructed with only two studies providing data at domain level (n=298 intervention, n=158 control)

  PMID:37852659 · one of two readings recorded this

• night-time asthma symptoms

  decreases

  0.15 (95% CI 0.09–0.21)

  PMID:37852659 · one of two readings recorded this

• night-time asthma symptoms

  increases

  Figure 4a and b shows forest plots of studies comparing patients with asthma treated with ICS versus montelukast in terms of daytime (n=386 intervention, n=376 control) and night-time (n=363 intervention, n=363 control) symptoms, which showed a statistically significant difference in favour of ICS

  PMID:37852659 · one of two readings recorded this

• adverse reactions (headache, dizziness, hoarseness, abdominal pain, total complications)

  no effect, p = 0.05

  the incidence of headache, dizziness, hoarseness, abdominal pain and total complications were not significantly different between groups (P > 0.05)

  PMID:38053076 · one of two readings recorded this

• cough disappearance time in days, pooled random-effects

  decreases, WMD -4.40 (-6.00, -2.79) days

  Not recorded as a finding: no outcome node for cough resolution time

  The pooled results showed that the cough symptom score (WMD (95% CI) = -0.33 (-0.67, 0.00), P = 0.05), the cough relief time (WMD (95% CI) = -2.72 (-3.54, -1.89) days, P < 0.001) and cough disappearance time (WMD (95% CI) = -4.40 (-6.00, -2.79) days, P < 0.001) in Mon + Flu group were significantly lower than those in the Flu group.

  PMID:38053076 · one of two readings recorded this

• cough disappearance time

  decreases, p = 0.001

  cough disappearance time (WMD (95% CI) = -4.40 (-6.00, -2.79) days, P < 0.001)

  PMID:38053076 · one of two readings recorded this

• cough recurrence rate, pooled RR

  decreases, RR 0.51 (0.31, 0.86), p = 0.01

  Not recorded as a finding: no outcome node for cough recurrence

  The pooled results showed that Flu + Mon significantly improved the total efficacy rate (RR (95% CI) = 1.30 (1.19, 1.43), P < 0.001) and reduced cough recurrence (RR (95% CI) = 0.51 (0.31, 0.86), P = 0.01).

  PMID:38053076 · one of two readings recorded this

• cough recurrence

  decreases, p = 0.01

  reduced cough recurrence (RR (95% CI) = 0.51 (0.31, 0.86), P = 0.01)

  PMID:38053076 · one of two readings recorded this

• cough relief (remission) time

  decreases, p = 0.001

  the cough relief time (WMD (95% CI) = -2.72 (-3.54, -1.89) days, P < 0.001)

  PMID:38053076 · one of two readings recorded this

• cough relief time and cough disappearance time in days, pooled WMD

  decreases, relief time WMD -2.72 days (-3.54, -1.89); disappearance time WMD -4.40 days (-6.00, -2.79)

  Not recorded as a finding: no outcome node for cough remission or disappearance time

  The pooled results showed that the cough symptom score (WMD (95% CI) = -0.33 (-0.67, 0.00), P = 0.05), the cough relief time (WMD (95% CI) = -2.72 (-3.54, -1.89) days, P < 0.001) and cough disappearance time (WMD (95% CI) = -4.40 (-6.00, -2.79) days, P < 0.001) in Mon + Flu group were significantly lower than those in the Flu group.

  PMID:38053076 · one of two readings recorded this

• cough symptom score

  decreases, p = 0.05

  the cough symptom score (WMD (95% CI) = -0.33 (-0.67, 0.00), P = 0.05)

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: abdominal pain

  no effect, p = 0.08

  Abdominal pain | 6 | 0.96 (0.35, 2.67) to 1.58 (0.48, 5.19) | Yes | 0.080

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: cough remission time

  no effect, p = 0.732

  Cough remission time | 3 | -3.19 (-3.87, -2.52) to -2.26 (-2.80, -1.72) | Yes | 0.732

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: dizzy

  no effect, p = 0.346

  Dizzy | 4 | 0.69 (0.11, 4.33) to 1.77 (0.29, 10.77) | Yes | 0.346

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: FEV1%

  no effect, p = 0.668

  FEV1% | 4 | 1.29 (-0.97, 3.54) to 3.30 (1.09, 5.50) | No | 0.668

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: headache

  no effect, p = 0.06

  Headache | 5 | 1.00 (0.20, 4.90) to 1.73 (0.35, 8.46) | Yes | 0.060

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: hoarseness

  no effect, p = 0.474

  Hoarseness | 6 | 0.70 (0.21, 2.37) to 1.00 (0.27, 3.63) | Yes | 0.474

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: PEF%

  no effect, p = 0.242

  PEF% | 4 | 1.73 (-0.73, 4.18) to 4.84 (0.13, 9.55) | No | 0.242

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: relapse rate

  no effect, p = 0.933

  Relapse rate | 6 | 0.42 (0.22, 0.79) to 0.60 (0.34, 1.05) | No | 0.933

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: score of cough

  no effect, p = 0.055

  The score of cough | 6 | -0.88 (-1.02, -0.74) to 0.00 (-0.28, 0.28) | No | 0.055

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: total complication

  no effect, p = 0.148

  Total complication | 9 | 0.98 (0.57, 1.71) to 1.15 (0.63, 2.09) | Yes | 0.148

  PMID:38053076 · one of two readings recorded this

• Egger's test publication bias: total effective rate

  no effect, p = 0.087

  Total effective rate | 5 | 1.30 (1.18, 1.43) to 1.34 (1.20, 1.50) | Yes | 0.087

  PMID:38053076 · one of two readings recorded this

• FEV1% recovery (percentage of forced expiratory volume in 1 second), pooled fixed-effect

  increases, WMD 2.65 (0.78, 4.52) %, p = 0.006

  Not recorded as a finding: fev1 node is a spirometric volume; the paper reports FEV1% (a percentage) and does not say whether it is percent predicted, so this is a near miss on the quantity

  The pooled results showed that, based on the fixed-effect model, the FEV1% recovery in Mon + Flu group was significantly better than that of the Flu group (WMD (95%CI) = 2.65 (0.78, 4.52) %, P = 0.006).

  PMID:38053076 · one of two readings recorded this

• FEV1% recovery

  increases, p = 0.006

  the FEV1% recovery in Mon + Flu group was significantly better than that of the Flu group (WMD (95%CI) = 2.65 (0.78, 4.52) %, P = 0.006)

  PMID:38053076 · one of two readings recorded this

• meta-regression of cough symptom score heterogeneity by sample size

  no effect, p = 0.757

  neither sample size (P=0.757) nor treatment cycle (P= 0.587) was significant factors influencing heterogeneity

  PMID:38053076 · one of two readings recorded this

• meta-regression of cough symptom score heterogeneity by treatment cycle

  no effect, p = 0.587

  neither sample size (P=0.757) nor treatment cycle (P= 0.587) was significant factors influencing heterogeneity

  PMID:38053076 · one of two readings recorded this

• PEF%

  no effect, p = 0.09

  the PEF% in Mon + Flu group was improved than that of the Flu group but without statistical significance (WMD (95%CI) = 3.64 (-0.59, 7.87) %, P = 0.09)

  PMID:38053076 · one of two readings recorded this

• total efficacy rate

  increases, p = 0.001

  The pooled results showed that Flu + Mon significantly improved the total efficacy rate (RR (95% CI) = 1.30 (1.19, 1.43), P < 0.001)

  PMID:38053076 · one of two readings recorded this

• Asthma Control Test score, change over time (mixed design ANOVA)

  no effect, p = 0.167

  A mixed design ANOVA revealed no statistically significant difference between the groups in changes in ACT scores over time (p = 0.167)

  PMID:40205376 · one of two readings recorded this

• Asthma Control Test score

  no effect, p = 0.14

  ACT score | 22.7 ± 1.92 | 22.45 ± 2.64 | 0.14 | 23.3 ± 1.7 | 23.5 ± 1.8 | 0.43 | 24.0 ± 1.45 | 22.4 ± 3.2 | 0.42

  PMID:40205376 · one of two readings recorded this

• Asthma Control Test score

  no effect, p = 0.43

  ACT score | 22.7 ± 1.92 | 22.45 ± 2.64 | 0.14 | 23.3 ± 1.7 | 23.5 ± 1.8 | 0.43 | 24.0 ± 1.45 | 22.4 ± 3.2 | 0.42

  PMID:40205376 · one of two readings recorded this

• Asthma Control Test score

  no effect, p = 0.42

  ACT score | 22.7 ± 1.92 | 22.45 ± 2.64 | 0.14 | 23.3 ± 1.7 | 23.5 ± 1.8 | 0.43 | 24.0 ± 1.45 | 22.4 ± 3.2 | 0.42

  PMID:40205376 · one of two readings recorded this

• change in ACT score from baseline

  unclear, p = 0.02

  Δ*** ACT score | - | - | - | 0.7 ± 1.73 | 1.3 ± 2.4 | 0.02 | 1.4 ± 2.3 | 0.4 ± 3.2 | 0.85

  PMID:40205376 · one of two readings recorded this

• change in ACT score from baseline

  no effect, p = 0.85

  Δ*** ACT score | - | - | - | 0.7 ± 1.73 | 1.3 ± 2.4 | 0.02 | 1.4 ± 2.3 | 0.4 ± 3.2 | 0.85

  PMID:40205376 · one of two readings recorded this

• change in daytime cough symptom score (D-NCS)

  no effect, p = 0.78

  Δ D-NCS | - | - | - | -0.5 ± 1.2 | -0.5 ± 1.1 | 0.78 | -0.7 ± 1.7 | -0.8 ± 1.2 | 0.62

  PMID:40205376 · one of two readings recorded this

• change in daytime cough symptom score (D-NCS)

  no effect, p = 0.62

  Δ D-NCS | - | - | - | -0.5 ± 1.2 | -0.5 ± 1.1 | 0.78 | -0.7 ± 1.7 | -0.8 ± 1.2 | 0.62

  PMID:40205376 · one of two readings recorded this

• change in FEV1/FVC

  no effect, p = 0.33

  Δ FEV1/FVC | - | - | - | 7.7 ± 13.3 | 9.5 ± 10.4 | 0.33 | 14.9 ± 12.7 | 12.1 ± 11.3 | 0.39

  PMID:40205376 · one of two readings recorded this

• change in FEV1/FVC

  no effect, p = 0.39

  Δ FEV1/FVC | - | - | - | 7.7 ± 13.3 | 9.5 ± 10.4 | 0.33 | 14.9 ± 12.7 | 12.1 ± 11.3 | 0.39

  PMID:40205376 · one of two readings recorded this

• change in FEV1

  no effect, p = 0.85

  Δ FEV1 | - | - | 14.8 ± 11.6 | 13.8 ± 10.9 | 0.85 | 20.2 ± 12.5 | 17.6 ± 12.3 | 0.93

  PMID:40205376 · one of two readings recorded this

• change in FEV1

  no effect, p = 0.93

  Δ FEV1 | - | - | 14.8 ± 11.6 | 13.8 ± 10.9 | 0.85 | 20.2 ± 12.5 | 17.6 ± 12.3 | 0.93

  PMID:40205376 · one of two readings recorded this

• change in FVC

  no effect, p = 0.08

  ΔFVC | - | - | - | 9.5 ± 8.6 | 9.1 ± 11.9 | 0.08 | 14.9 ± 12.8 | 12.2 ± 11.3 | 0.64

  PMID:40205376 · one of two readings recorded this

• change in FVC

  no effect, p = 0.64

  ΔFVC | - | - | - | 9.5 ± 8.6 | 9.1 ± 11.9 | 0.08 | 14.9 ± 12.8 | 12.2 ± 11.3 | 0.64

  PMID:40205376 · one of two readings recorded this

• change in nighttime cough symptom score (N-NCS)

  no effect, p = 0.83

  Δ N-NCS | - | - | - | -0.4 ± 1.5 | -0.7 ± 1.4 | 0.83 | -0.6 ± 1.8 | -1.1 ± 1.6 | 0.85

  PMID:40205376 · one of two readings recorded this

• change in nighttime cough symptom score (N-NCS)

  no effect, p = 0.85

  Δ N-NCS | - | - | - | -0.4 ± 1.5 | -0.7 ± 1.4 | 0.83 | -0.6 ± 1.8 | -1.1 ± 1.6 | 0.85

  PMID:40205376 · one of two readings recorded this

• daytime cough symptom score (D-NCS)

  no effect, p = 0.4

  D-NCS | 1.23 ± 1.33 | 1.34 ± 1.28 | 0.50 | 0.7 ± 0.5 | 0.8 ± 0.8 | 0.40 | 0.6 ± 0.9 | 0.5 ± 0.5 | 0.61

  PMID:40205376 · one of two readings recorded this

• daytime cough symptom score (D-NCS)

  no effect, p = 0.61

  D-NCS | 1.23 ± 1.33 | 1.34 ± 1.28 | 0.50 | 0.7 ± 0.5 | 0.8 ± 0.8 | 0.40 | 0.6 ± 0.9 | 0.5 ± 0.5 | 0.61

  PMID:40205376 · one of two readings recorded this

• FEV1/FVC

  no effect, p = 0.27

  FEV1/FVC (%) | 81.19 ± 14.84 | 75.47 ± 10.19 | 0.10 | 87.5 ± 11.7 | 85.2 ± 9.8 | 0.27 | 84.9 ± 10.1 | 88.6 ± 7.61 | 0.56

  PMID:40205376 · one of two readings recorded this

• FEV1/FVC

  no effect, p = 0.56

  FEV1/FVC (%) | 81.19 ± 14.84 | 75.47 ± 10.19 | 0.10 | 87.5 ± 11.7 | 85.2 ± 9.8 | 0.27 | 84.9 ± 10.1 | 88.6 ± 7.61 | 0.56

  PMID:40205376 · one of two readings recorded this

• FEV1

  no effect, p = 0.85

  FEV1 | 70.62 ± 16.69 | 73.28 ± 15.08 | 0.53 | 85.6 ± 10.4 | 84.5 ± 10.8 | 0.85 | 91.5 ± 8.8 | 86.9 ± 6.1 | 0.14

  PMID:40205376 · one of two readings recorded this

• FEV1

  no effect, p = 0.14

  FEV1 | 70.62 ± 16.69 | 73.28 ± 15.08 | 0.53 | 85.6 ± 10.4 | 84.5 ± 10.8 | 0.85 | 91.5 ± 8.8 | 86.9 ± 6.1 | 0.14

  PMID:40205376 · one of two readings recorded this

• FVC

  no effect, p = 0.68

  FVC | 79.36 ± 13.26 | 84.76 ± 17.48 | 0.17 | 89.6 ± 10.9 | 89.3 ± 10.1 | 0.68 | 95.0 ± 10.0 | 91.5 ± 6.14 | 0.35

  PMID:40205376 · one of two readings recorded this

• FVC

  no effect, p = 0.35

  FVC | 79.36 ± 13.26 | 84.76 ± 17.48 | 0.17 | 89.6 ± 10.9 | 89.3 ± 10.1 | 0.68 | 95.0 ± 10.0 | 91.5 ± 6.14 | 0.35

  PMID:40205376 · one of two readings recorded this

• medication adherence

  no effect, p = 0.88

  Adherence (%) | 100 | 100 | - | 97.1 | 100 | 0.88 | 94.2 | 91.6 | 0.89

  PMID:40205376 · one of two readings recorded this

• medication adherence

  no effect, p = 0.89

  Adherence (%) | 100 | 100 | - | 97.1 | 100 | 0.88 | 94.2 | 91.6 | 0.89

  PMID:40205376 · one of two readings recorded this

• nighttime cough symptom score (N-NCS)

  no effect, p = 0.26

  N-NCS | 1.35 ± 0.73 | 1.50 ± 1.14 | 0.16 | 0.3 ± 0.2 | 0.4 ± 0.7 | 0.26 | 0.3 ± 0.3 | 0.2 ± 0.4 | 0.17

  PMID:40205376 · one of two readings recorded this

• nighttime cough symptom score (N-NCS)

  no effect, p = 0.17

  N-NCS | 1.35 ± 0.73 | 1.50 ± 1.14 | 0.16 | 0.3 ± 0.2 | 0.4 ± 0.7 | 0.26 | 0.3 ± 0.3 | 0.2 ± 0.4 | 0.17

  PMID:40205376 · one of two readings recorded this

• treatment failure (number of patients)

  no effect, p = 0.14

  Treatment failure (number of patients) | - | - | - | 0 | 2 | 0.14 | 0 | 5 | 0.01

  PMID:40205376 · one of two readings recorded this

• treatment failure (number of patients)

  decreases, p = 0.01

  Treatment failure (number of patients) | - | - | - | 0 | 2 | 0.14 | 0 | 5 | 0.01

  PMID:40205376 · one of two readings recorded this

• treatment failure rate, Group ICS (montelukast discontinuation)

  increases

  two patients (6%) experienced treatment failure at one month, and five patients (16%) experienced treatment failure at three months

  PMID:40205376 · one of two readings recorded this

• treatment failure rate, Group ICS (montelukast discontinuation)

  increases

  two patients (6%) experienced treatment failure at one month, and five patients (16%) experienced treatment failure at three months

  PMID:40205376 · one of two readings recorded this

• treatment failure rate (sustained fall in Asthma Control Test score below 20) and ACT score at 3 months, montelukast discontinuation with ICS dose maintained versus ICS dose reduction with montelukast continued, in adults with well-controlled asthma

  no effect, p = 0.167

  Not recorded as a finding: the comparison was against another active treatment

  A mixed design ANOVA revealed no statistically significant difference between the groups in changes in ACT scores over time (p = 0.167).

  PMID:40205376 · one of two readings recorded this

• baseline age

  no effect, p = 0.531, n = 267

  Age | 37 (27.5–45.5) | 37 (28–47) |.531

  PMID:40419876 · one of two readings recorded this

• baseline BMI

  no effect, p = 0.188, n = 267

  BMI | 20.9 (19.55–23.55) | 20.4 (19.28–23.4) |.188

  PMID:40419876 · one of two readings recorded this

• baseline disease duration

  no effect, p = 0.723, n = 267

  Duration | 5 (4.5–7) | 5 (5–7) |.723

  PMID:40419876 · one of two readings recorded this

• baseline proportion male

  no effect, p = 0.535, n = 267

  Male | 61 (46%) | 57 (43%) |.535

  PMID:40419876 · one of two readings recorded this

• baseline weight

  no effect, p = 0.623, n = 267

  Weight | 61 (55–70) | 62 (55–72) |.623

  PMID:40419876 · one of two readings recorded this

• RQLQ domain scores (daily living, nonnasal and ocular symptoms, behavioral problems, nasal symptoms, ocular symptoms)

  decreases, n = 267

  with the differences in the 5 scores of daily living, nonnasal and ocular symptoms, behavioral problems, nasal symptoms, and ocular symptoms being statistically significant after 2 weeks of treatment

  PMID:40419876 · one of two readings recorded this

• total RQLQ score

  decreases, n = 267

  the total RQLQ scores in both groups showed a significant decrease, after 2 and 4 weeks of treatment compared with the baseline values, the decrease was more pronounced in the BCQB + MNT group

  PMID:40419876 · one of two readings recorded this

• total VAS symptom score, between-group after treatment

  decreases, n = 267

  Moreover, a significant difference in the total VAS scores was found between the MNT group and the BCQB + MNT group after treatment

  PMID:40419876 · one of two readings recorded this

• total VAS symptom score, within-group vs baseline

  decreases, n = 267

  the total VAS scores revealed a significant decrease in both groups compared with the baseline values

  PMID:40419876 · one of two readings recorded this

• VAS nasal congestion

  decreases, n = 267

  These 2 symptoms showed differences as early as week 2 of treatment while sneezing symptoms showed differences only by week 4

  PMID:40419876 · one of two readings recorded this

• VAS nasal symptoms (4 typical), within-group vs baseline

  decreases, n = 267

  Compared with the baseline group, all 4 typical nasal symptom scores significantly decreased at week 4

  PMID:40419876 · one of two readings recorded this

• VAS rhinorrhea

  decreases, n = 267

  These 2 symptoms showed differences as early as week 2 of treatment while sneezing symptoms showed differences only by week 4

  PMID:40419876 · one of two readings recorded this

• VAS sneezing

  decreases, n = 267

  These 2 symptoms showed differences as early as week 2 of treatment while sneezing symptoms showed differences only by week 4

  PMID:40419876 · one of two readings recorded this

• daytime and nighttime total nasal symptom scores, individual nasal and eye symptoms, RQLQ and treatment-emergent adverse events, combination montelukast plus levocetirizine versus montelukast or levocetirizine monotherapy

  no effect, TEAE OR 1.05, 95% CI 0.57 to 1.94, combination versus monotherapy

  Not recorded as a finding: the comparison was against another active treatment

  The pooled analysis showed no statistically significant difference in the overall incidence of TEAEs between combination therapy and monotherapy (OR [95% CI]: 1.05 [0.57 to 1.94]; I2 = 51.1%).

  PMID:40664175 · one of two readings recorded this

• daytime total nasal symptom score (four-point diary scale), montelukast plus levocetirizine versus monotherapy with either montelukast or levocetirizine

  decreases, SMD −0.42 [−0.64 to −0.20]

  Not recorded as a finding: the comparison was against another active treatment

  Combination therapy resulted in a significantly greater reduction in daytime total symptom score, based on data from 902 participants (450 in the combination group vs. 452 in the monotherapy group) (SMD [95% CI]: −0.42 [−0.64 to −0.20]; I2 = 58%).

  PMID:40664175 · one of two readings recorded this

• daytime total symptom score

  decreases, n = 902

  a significantly greater reduction in daytime total symptom score, based on data from 902 participants (450 in the combination group vs. 452 in the monotherapy group) (SMD [95% CI]: −0.42 [−0.64 to −0.20]; I2 = 58%)

  PMID:40664175 · one of two readings recorded this

• daytime total symptom score

  decreases

  Compared with levocetirizine monotherapy, combination therapy showed greater improvements in daytime symptom scores (SMD [95% CI]: −0.48 [−0.83 to −0.13]; I2 = 50%)

  PMID:40664175 · one of two readings recorded this

• daytime total symptom score

  decreases

  In comparison to montelukast monotherapy, combination therapy showed superior efficacy for both daytime (SMD [95% CI]: −0.42 [−0.82 to −0.02]; I2 = 67%)

  PMID:40664175 · one of two readings recorded this

• eye symptoms

  decreases

  Eye symptoms also improved significantly (SMD [95% CI]: −0.98 [−1.94 to −0.02]; I2 = 96.7%)

  PMID:40664175 · one of two readings recorded this

• eye symptoms

  no effect

  levocetirizine: SMD [95% CI]: −0.75 [−2.11 to 0.61]; I2 = 97.2%

  PMID:40664175 · one of two readings recorded this

• eye symptoms

  no effect

  montelukast: SMD [95% CI]: −1.30 [−2.85 to 0.26]; I2 = 96.7%

  PMID:40664175 · one of two readings recorded this

• nasal congestion

  decreases

  For nasal congestion, combination therapy produced a moderate-to-large effect size (SMD [95% CI]: −0.64 [−1.05 to −0.24]; I2 = 73.1%)

  PMID:40664175 · one of two readings recorded this

• nasal congestion

  decreases

  nasal congestion (SMD [95% CI]: −0.92 [−1.37 to −0.47]; I2 = 0%)

  PMID:40664175 · one of two readings recorded this

• nasal congestion

  decreases

  nasal congestion (SMD [95% CI]: −0.54 [−1.07 to −0.00]; I2 = 75.7%)

  PMID:40664175 · one of two readings recorded this

• nasal itching

  decreases

  Nasal itching also improved significantly (SMD [95% CI]: −0.36 [−0.56 to −0.16]; I2 = 0%)

  PMID:40664175 · one of two readings recorded this

• nasal itching

  decreases

  itching (SMD [95% CI]: −0.49 [−0.92 to −0.06]; I2 = 0%)

  PMID:40664175 · one of two readings recorded this

• nasal itching

  decreases

  nasal itching (SMD [95% CI]: −0.32 [−0.55 to −0.09]; I2 = 0.0%)

  PMID:40664175 · one of two readings recorded this

• nighttime total symptom score

  decreases, n = 822

  A smaller but statistically significant reduction was also observed in nighttime total symptom score, based on 822 participants (410 vs. 412) (SMD [95% CI]: −0.21 [−0.35 to −0.07]; I2 = 0%)

  PMID:40664175 · one of two readings recorded this

• nighttime total symptom score

  no effect

  the reduction in nighttime symptoms did not reach statistical significance (SMD [95% CI]: −0.20 [−0.45 to 0.05]; I2 = 0%)

  PMID:40664175 · one of two readings recorded this

• nighttime total symptom score

  decreases

  nighttime symptoms (SMD [95% CI]: −0.22 [−0.39 to −0.05]; I2 = 0%)

  PMID:40664175 · one of two readings recorded this

• rhinoconjunctivitis quality of life (RQLQ)

  decreases, n = 557

  combination therapy was associated with a modest improvement in RQLQ scores in 557 participants (275 vs. 282), although the pooled effect size was limited and between-study heterogeneity was high (SMD [95% CI]: −0.37 [−0.72 to −0.01]; I2 = 77%)

  PMID:40664175 · one of two readings recorded this

• rhinoconjunctivitis quality of life (RQLQ)

  no effect

  subgroup comparisons for RQLQ did not reveal statistically significant differences when compared with either levocetirizine (SMD [95% CI]: −0.44 [−1.03 to 0.15])

  PMID:40664175 · one of two readings recorded this

• rhinoconjunctivitis quality of life (RQLQ)

  no effect

  montelukast (SMD [95% CI]: −0.25 [−0.53 to 0.02])

  PMID:40664175 · one of two readings recorded this

• rhinorrhea

  decreases

  The greatest improvement was observed in rhinorrhea (SMD [95% CI]: −0.69 [−1.09 to −0.30]; I2 = 80.1%)

  PMID:40664175 · one of two readings recorded this

• rhinorrhea

  decreases

  rhinorrhea (SMD [95% CI]: −0.43 [−0.78 to −0.07]; I2 = 37.5%)

  PMID:40664175 · one of two readings recorded this

• rhinorrhea

  decreases

  rhinorrhea (SMD [95% CI]: −0.91 [−1.59 to −0.22]; I2 = 80.4%)

  PMID:40664175 · one of two readings recorded this

• sneezing

  decreases

  Sneezing showed a greater reduction with combination therapy (SMD [95% CI]: −0.63 [−0.93 to −0.33]; I2 = 42.3%)

  PMID:40664175 · one of two readings recorded this

• sneezing

  decreases

  sneezing (SMD [95% CI]: −0.69 [−1.12 to −0.25]; I2 = 0%)

  PMID:40664175 · one of two readings recorded this

• sneezing

  decreases

  sneezing (SMD [95% CI]: −0.52 [−0.75 to −0.29]; I2 = 67.3%)

  PMID:40664175 · one of two readings recorded this

• treatment-emergent adverse events (mild)

  no effect

  mild events (OR [95% CI]: 1.11 [0.70 to 1.77]; I2 = 15.8%)

  PMID:40664175 · one of two readings recorded this

• treatment-emergent adverse events (moderate)

  no effect

  moderate events (OR [95% CI]: 1.57 [0.34 to 7.36]; I2 = 57.1%)

  PMID:40664175 · one of two readings recorded this

• treatment-emergent adverse events (overall)

  no effect

  no statistically significant difference in the overall incidence of TEAEs between combination therapy and monotherapy (OR [95% CI]: 1.05 [0.57 to 1.94]; I2 = 51.1%)

  PMID:40664175 · one of two readings recorded this

• treatment-emergent adverse events (severe)

  no effect

  severe events (OR [95% CI]: 1.30 [0.28 to 6.11]; I2 = 0%)

  PMID:40664175 · one of two readings recorded this

• urea

  no effect, p = 0.068, n = 25

  Urea (mg/dl) | Control group | 28(22.4–35.4) | 27.9(20.1–34.6) | 23.3(18.3–31.4) | 22.8(19.1–33.7) | Frp = 0.068

  PMID:41034674 · one of two readings recorded this

• urea

  no effect, p = 0.277, n = 25

  ML group | 25.2(23.3–29.1) | 24.2(19.2–30.3) | 23.8(21.2–31.4) | 22.1(17.4–26.6) | Frp = 0.277

  PMID:41034674 · one of two readings recorded this

• hemoglobin

  decreases, p = 0.001, n = 25

  Hemoglobin (g/dl) | Control group | 12.79 ± 1.39 | 12.36 ± 1.08 | 12.26 ± 0.89 | 11.84 ± 1.0 | Fp < 0.001*

  PMID:41034674 · one of two readings recorded this

• hemoglobin

  decreases, p = 0.001, n = 25

  ML group | 12.70 ± 1.12 | 11.93 ± 1.06 | 11.96 ± 1.04 | 11.85 ± 0.95 | Fp < 0.001*

  PMID:41034674 · one of two readings recorded this

• MCH

  no effect, p = 0.096, n = 25

  MCH (pg) | Control group | 26.73 ± 2.17 | 26.93 ± 1.79 | 27.30 ± 2.36 | 27.31 ± 2.68 | Fp = 0.096

  PMID:41034674 · one of two readings recorded this

• MCH

  no effect, p = 0.081, n = 25

  ML group | 27.0 ± 2.54 | 27.07 ± 1.81 | 27.07 ± 1.82 | 27.66 ± 1.77 | Fp = 0.081

  PMID:41034674 · one of two readings recorded this

• AST

  no effect, p = 0.161, n = 25

  AST(IU/l) | Control group | 24.4 (19–29) | 25.7(23.4–30) | 27.3(25.4–29.3) | 29.8 (25.3–33) | Frp = 0.161

  PMID:41034674 · one of two readings recorded this

• AST

  increases, p = 0.001, n = 25

  ML group | 22 (19–24) | 28.3(23–30.8) | 23.3(20.9–27.3) | 30 (24.5–34.7) | Frp < 0.001*

  PMID:41034674 · one of two readings recorded this

• absolute lymphocyte count

  decreases, p = 0.007, n = 25

  Lymphocytes absolute (/cm) | Control group | 2.44 ± 0.83 | 2.14 ± 0.63 | 2.03 ± 0.59 | 1.96 ± 0.62 | Fp = 0.007*

  PMID:41034674 · one of two readings recorded this

• absolute lymphocyte count

  decreases, p = 0.001, n = 25

  ML group | 2.45 ± 0.74 | 2.01 ± 0.88 | 1.88 ± 0.69 | 1.68 ± 0.53 | Fp < 0.001*

  PMID:41034674 · one of two readings recorded this

• absolute neutrophil count

  decreases, p = 0.008, n = 25

  Neutrophils absolute (/cm) | Control group | 4.85 ± 2.82 | 4.29 ± 3.19 | 3.22 ± 1.37 | 3.0 ± 1.30 | Fp = 0.008*

  PMID:41034674 · one of two readings recorded this

• absolute neutrophil count

  decreases, p = 0.015, n = 25

  ML group | 3.86 ± 1.71 | 3.03 ± 1.75 | 2.56 ± 1.13 | 3.07 ± 1.44 | Fp = 0.015*

  PMID:41034674 · one of two readings recorded this

• ALT

  no effect, p = 0.352, n = 25

  ALT (IU/l) | Control group | 20 (15.8–31) | 23 (19–31) | 22 (18–25) | 23.7 (17.9–30) | Frp = 0.352

  PMID:41034674 · one of two readings recorded this

• ALT

  increases, p = 0.009, n = 25

  ML group | 16 (13–18.2) | 21.7 (17.9–27) | 20 (17.5–26.3) | 22 (20–31.4) | Frp = 0.009*

  PMID:41034674 · one of two readings recorded this

• arm lymphedema incidence

  decreases, p = 0.01, n = 50

  the ML group experienced less arm lymphedema (24% vs. 60%) (p = 0.010)

  PMID:41034674 · one of two readings recorded this

• AST in cycle 3, between-group

  decreases, p = 0.005, n = 50

  AST demonstrated a significant decrease in cycle 3 when compared to its comparable control (p = 0.005)

  PMID:41034674 · one of two readings recorded this

• correlation NF-κB vs sST2

  no effect, p = 0.708, n = 50

  NF-κB vs. sST2 | −0.054 | 0.708 | 0.104 | 0.471

  PMID:41034674 · one of two readings recorded this

• correlation NT-proBNP vs NF-κB

  increases, p = 0.001, n = 50

  NT-proBNP vs. NF-κB | 0.619* | < 0.001* | 0.644* | < 0.001*

  PMID:41034674 · one of two readings recorded this

• correlation NT-proBNP vs sST2

  no effect, p = 0.511, n = 50

  NT-proBNP vs. sST2 | −0.095 | 0.511 | 0.138 | 0.338

  PMID:41034674 · one of two readings recorded this

• fasting plasma glucose

  no effect, p = 0.605, n = 25

  Fasting plasma glucose (mg/dl) | Control group | 118.5(100–128) | 112(102–129.8) | 108(102.2–130.6) | 115(106–125) | Frp = 0.605

  PMID:41034674 · one of two readings recorded this

• fasting plasma glucose

  no effect, p = 0.138, n = 25

  ML group | 104(97–112.4) | 107(99.6–114.9) | 103.3(96–115) | 103(95–116) | Frp = 0.138

  PMID:41034674 · one of two readings recorded this

• hematocrit

  decreases, p = 0.001, n = 25

  Hematocrit (%) | Control group | 38.83 ± 4.22 | 37.82 ± 2.94 | 37.26 ± 3.53 | 35.92 ± 3.24 | Fp = 0.001*

  PMID:41034674 · one of two readings recorded this

• hematocrit

  decreases, p = 0.001, n = 25

  ML group | 38.60 ± 3.22 | 36.60 ± 2.82 | 36.20 ± 3.12 | 36.06 ± 3.08 | Fp < 0.001*

  PMID:41034674 · one of two readings recorded this

• MCHC

  no effect, p = 0.813, n = 25

  MCHC (g/dL) | Control group | 32.93 ± 1.39 | 32.67 ± 1.04 | 33.0 ± 1.79 | 33.05 ± 1.96 | Fp = 0.813

  PMID:41034674 · one of two readings recorded this

• MCHC

  no effect, p = 0.427, n = 25

  ML group | 33.29 ± 2.61 | 32.63 ± 1.87 | 33.02 ± 1.66 | 32.41 ± 2.28 | Fp = 0.427

  PMID:41034674 · one of two readings recorded this

• MCV

  no effect, p = 0.418, n = 25

  MCV (FL) | Control group | 81.03 ± 6.41 | 82.14 ± 6.23 | 82.31 ± 7.19 | 82.84 ± 7.31 | Fp = 0.418

  PMID:41034674 · one of two readings recorded this

• MCV

  no effect, p = 0.063, n = 25

  ML group | 81.11 ± 5.72 | 82.60 ± 6.14 | 82.11 ± 6.64 | 84.20 ± 6.67 | Fp = 0.063

  PMID:41034674 · one of two readings recorded this

• plasma NF-κB, between-group after treatment

  decreases, p = 0.009, n = 50

  The ML group showed a significantly lower NF-κB levels after treatment compared to the control group (2.23 [1.18–3.05] vs. 3.11 [2.39–3.25] pg/mL, p = 0.009)

  PMID:41034674 · one of two readings recorded this

• plasma NF-κB, within-group change

  increases, p = 0.026, n = 25

  the control group had significantly higher levels of the marker, with a median of 3.11 pg/mL (p = 0.026)

  PMID:41034674 · one of two readings recorded this

• plasma NF-κB, within-group change

  decreases, p = 0.048, n = 25

  the ML group showed a significant reduction to 2.23 pg/mL (p = 0.048)

  PMID:41034674 · one of two readings recorded this

• plasma NT-proBNP after four cycles of doxorubicin-cyclophosphamide, ELISA, in breast cancer patients given montelukast 10 mg daily or no montelukast (chemotherapy in both arms); also NF-kB and sST2 by ELISA

  decreases, median NT-proBNP 1756.0 [1054.0–2334.0] vs 3788.0 [2226.0–4401.1] pg/mL, montelukast group versus control

  Not recorded as a finding: this platform holds no node for the endpoint

  The between-group comparison by the end of treatment revealed a statistically significant difference, with the ML group achieving much lower levels compared to the control group (1756.0 [1054.0–2334.0] vs. 3788.0 [2226.0–4401.1] pg/mL, p < 0.001).

  PMID:41034674 · one of two readings recorded this

• plasma NT-proBNP after four cycles of doxorubicin plus cyclophosphamide, ELISA, montelukast (ML) added to chemotherapy versus chemotherapy alone in breast cancer; also plasma NF-kB and soluble ST2, ELISA

  decreases, ML 1756.0 [1054.0-2334.0] vs control 3788.0 [2226.0-4401.1] pg/mL

  Not recorded as a finding: this platform holds no node for the endpoint

  The between-group comparison by the end of treatment revealed a statistically significant difference, with the ML group achieving much lower levels compared to the control group (1756.0 [1054.0–2334.0] vs. 3788.0 [2226.0–4401.1] pg/mL, p < 0.001).

  PMID:41034674 · one of two readings recorded this

• plasma NT-proBNP, between-group after treatment

  decreases, p = 0.001, n = 50

  the ML group achieving much lower levels compared to the control group (1756.0 [1054.0–2334.0] vs. 3788.0 [2226.0–4401.1] pg/mL, p < 0.001)

  PMID:41034674 · one of two readings recorded this

• plasma NT-proBNP, between-group at baseline

  no effect, p = 0.749, n = 50

  At baseline, there was an insignificant difference in NT-proBNP levels between the two groups (p = 0.749)

  PMID:41034674 · one of two readings recorded this

• plasma NT-proBNP, within-group change

  increases, p = 0.001, n = 25

  the control group exhibited a significant increase in median values (2040.9 vs 3788.0 pg/mL, p < 0.001)

  PMID:41034674 · one of two readings recorded this

• plasma NT-proBNP, within-group change

  decreases, p = 0.037, n = 25

  while the ML group showed a significant reduction (1817.2 vs 1756.0 pg/mL, p = 0.037)

  PMID:41034674 · one of two readings recorded this

• plasma sST2, between-group after treatment

  decreases, p = 0.036, n = 50

  the ML group's sST2 levels (20.93 ± 5.45 ng/mL) demonstrated a significant decrease (p = 0.036) in comparison to its corresponding control group (24.16 ± 5.14 ng/mL)

  PMID:41034674 · one of two readings recorded this

• plasma sST2, between-group at baseline

  no effect, p = 0.747, n = 50

  the control and ML groups' baseline sST2 levels did not differ significantly (p = 0.747)

  PMID:41034674 · one of two readings recorded this

• plasma sST2, within-group change

  no effect, p = 0.98, n = 25

  there was no significant change in the control group's sST2 levels before and after therapy (p = 0.980)

  PMID:41034674 · one of two readings recorded this

• plasma sST2, within-group change

  no effect, p = 0.061, n = 25

  Even though the ML group's sST2 levels decreased (24.91 ± 7.91 vs. 20.93 ± 5.45), the difference was not statistically significant (p = 0.061)

  PMID:41034674 · one of two readings recorded this

• platelet count, between-group

  modulates, p = 0.001, n = 50

  Compared to the control group, the ML group's platelet counts changed significantly (p < 0.001)

  PMID:41034674 · one of two readings recorded this

• platelet count

  no effect, p = 0.118, n = 25

  PLT (× 103/μl) | Control group | 321.4 ± 180.41 | 397.0 ± 150.73 | 375.9 ± 109.80 | 364.3 ± 104.15 | Fp = 0.118

  PMID:41034674 · one of two readings recorded this

• platelet count

  increases, p = 0.001, n = 25

  ML group | 289.8 ± 71.51 | 398.0 ± 123.96 | 350.7 ± 80.54 | 353.3 ± 95.35 | Fp < 0.001*

  PMID:41034674 · one of two readings recorded this

• RDW/CV

  increases, p = 0.002, n = 25

  RDW/CV (%) | Control group | 14.92 ± 1.34 | 14.37 ± 1.67 | 15.22 ± 1.86 | 15.87 ± 2.03 | Fp = 0.002*

  PMID:41034674 · one of two readings recorded this

The whole record — 277 rows